Researchers explored HER2 testing discordance, biomarkers of response, patient-reported outcomes, and the risk of lung-related disease.

Delcath Systems, Inc. , an interventional oncology company focused on liver-directed cancer therapies, today announced the presentation of new subgroup analysis data from the FOCUS Phase 3 trial of ...

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on liver-directed cancer therapies, today announced the presentation of new subgroup analysis data from the FOCUS Phase ...

ORRs of 54.8% and 50.0% achieved in locally advanced and metastatic cSCC, with median follow-up durations of 24.1 and 29.3 months, respectively. Results demonstrate a deepening of response over time, ...

Research highlights the use of multimodal machine learning to identify non-small cell lung cancer patients predicted to ...

ImmVira announced the latest clinical results for its lead oncolytic virus product, MVR-T3011, via intravesical ...

Indeed, the global oncology community trusts ESMO to disseminate the latest results of cancer research. Why? Because it is ...

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, will be presenting multiple posters at the European Society for Medical ...

The global collective intelligence network aims to accelerate precision oncology research and care ...

What's the BIOSECURE Act? Why is Merck nonchalant about Summit's Keytruda rival? What did Roivant buy from Bayer? We answer ...

At WCLC, five-year survival data to be presented on Libtayo (PD-1 inhibitor) first-line monotherapy in advanced non-small cell lung cancerAt ...

They can also replace missing teeth and repair chips. Not all of the available cosmetic dental procedures will work for everyone. Your dentist can help you determine which method will work the best ...